Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)
120.62 x 1 136.00 x 3
Pre-market by (Cboe BZX)
120.49 -0.02 (-0.02%) 02/26/25 [NYSE]
120.62 x 1 136.00 x 3
Pre-market 120.49 unch (unch) 19:00 ET
Quote Overview for Wed, Feb 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
119.41
Day High
124.30
Open 121.53
Previous Close 120.51 120.51
Volume 948,100 948,100
Avg Vol 883,875 883,875
Stochastic %K 6.40% 6.40%
Weighted Alpha +17.37 +17.37
5-Day Change -40.09 (-24.97%) -40.09 (-24.97%)
52-Week Range 83.90 - 163.71 83.90 - 163.71
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,643,457
  • Shares Outstanding, K 55,137
  • Annual Sales, $ 383,480 K
  • Annual Income, $ -146,370 K
  • EBIT $ -122 M
  • EBITDA $ -85 M
  • 60-Month Beta 1.04
  • Price/Sales 17.33
  • Price/Cash Flow N/A
  • Price/Book 8.93

Options Overview Details

View History
  • Implied Volatility 49.50% ( +5.33%)
  • Historical Volatility 71.36%
  • IV Percentile 67%
  • IV Rank 33.81%
  • IV High 84.37% on 11/01/24
  • IV Low 31.68% on 08/27/24
  • Put/Call Vol Ratio 2.67
  • Today's Volume 88
  • Volume Avg (30-Day) 1,290
  • Put/Call OI Ratio 1.41
  • Today's Open Interest 8,867
  • Open Int (30-Day) 8,672

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 9
  • High Estimate -0.26
  • Low Estimate -0.39
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +52.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
116.21 +3.69%
on 02/25/25
Period Open: 160.22
161.78 -25.52%
on 02/19/25
-39.73 (-24.80%)
since 01/24/25
3-Month
116.21 +3.69%
on 02/25/25
Period Open: 140.73
163.71 -26.40%
on 01/23/25
-20.24 (-14.38%)
since 11/26/24
52-Week
83.90 +43.61%
on 03/05/24
Period Open: 91.63
163.71 -26.40%
on 01/23/25
+28.86 (+31.50%)
since 02/26/24

Most Recent Stories

More News
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

Glaukos Corporation GKOS reported fourth-quarter 2024 adjusted loss of 40 cents per share, narrower than the Zacks Consensus Estimate of a loss of 43 cents. The figure also improved from the year-ago...

AVAH : 4.22 (-0.71%)
MASI : 190.47 (+12.35%)
GKOS : 120.49 (-0.02%)
ATEC : 11.06 (+4.73%)
Glaukos: Q4 Earnings Snapshot

Glaukos: Q4 Earnings Snapshot

GKOS : 120.49 (-0.02%)
What to Expect From These 3 MedTech Stocks This Earnings Season?

As the fourth-quarter earnings season progresses, this week will be crucial for many companies in the medical device sector. According to the latest Earnings Preview report, the Medical sector is poised...

AMN : 25.96 (-0.84%)
ITGR : 126.27 (-1.15%)
GKOS : 120.49 (-0.02%)
Insider Sale: Director at $GKOS (GKOS) Sells 2,000 Shares

Gilbert H Kliman, a director at $GKOS ($GKOS), sold 2,000 shares of the company on 12-11-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.8% of their shares....

GKOS : 120.49 (-0.02%)
Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #2 (Buy)...

AXGN : 19.46 (-3.23%)
ARAY : 2.05 (+1.49%)
MASI : 190.47 (+12.35%)
GKOS : 120.49 (-0.02%)
Glaukos: Q3 Earnings Snapshot

Glaukos: Q3 Earnings Snapshot

GKOS : 120.49 (-0.02%)
Glaukos: Q2 Earnings Snapshot

Glaukos: Q2 Earnings Snapshot

GKOS : 120.49 (-0.02%)
Stocks Climb on Strength in Chips Stocks and Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. US stock indexes this morning...

$SPX : 5,956.06 (+0.01%)
SPY : 594.54 (+0.05%)
$DOWI : 43,433.12 (-0.43%)
DIA : 434.34 (-0.41%)
$IUXX : 21,132.92 (+0.22%)
QQQ : 514.56 (+0.24%)
ZNM25 : 110-185 (-0.28%)
MU : 97.71 (+4.82%)
NVDA : 131.28 (+3.67%)
AMD : 104.74 (+0.75%)
GFS : 40.61 (-0.07%)
KLAC : 738.52 (+1.87%)
Stocks Push Higher on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. US stock indexes this morning...

$SPX : 5,956.06 (+0.01%)
SPY : 594.54 (+0.05%)
$DOWI : 43,433.12 (-0.43%)
DIA : 434.34 (-0.41%)
$IUXX : 21,132.92 (+0.22%)
QQQ : 514.56 (+0.24%)
ZNM25 : 110-185 (-0.28%)
PARA : 11.22 (-2.43%)
MU : 97.71 (+4.82%)
IR : 83.36 (-0.04%)
FRPT : 106.88 (-0.15%)
PRFT : 75.96 (+0.64%)
Glaukos: Q1 Earnings Snapshot

Glaukos: Q1 Earnings Snapshot

GKOS : 120.49 (-0.02%)
Glaukos: Q4 Earnings Snapshot

Glaukos: Q4 Earnings Snapshot

GKOS : 120.49 (-0.02%)
Moderna, Rivian rise; Apellis, Adobe fall, Thursday, 12/14/2023

Stocks that traded heavily or had substantial price changes on Thursday: Moderna, Rivian rise; Apellis, Adobe fall

HES : 145.47 (-1.01%)
MRNA : 33.58 (+0.90%)
APLS : 26.33 (-2.12%)
GKOS : 120.49 (-0.02%)
T : 26.57 (-0.30%)
ADBE : 441.50 (-0.43%)
MKKGY : 28.5200 (-1.08%)
Glaukos: Q3 Earnings Snapshot

Glaukos: Q3 Earnings Snapshot

GKOS : 120.49 (-0.02%)
Glaukos: Q2 Earnings Snapshot

Glaukos: Q2 Earnings Snapshot

GKOS : 120.49 (-0.02%)
These 2 Soaring Stocks Finished the Week Strong

Wall Street coasted into the close on Friday but still had a good week.

COMP : 9.45 (+2.16%)
$NASX : 19,075.26 (+0.26%)
$SPX : 5,956.06 (+0.01%)
$DOWI : 43,433.12 (-0.43%)
AEHR : 10.03 (+1.01%)
GKOS : 120.49 (-0.02%)
WFC : 76.45 (+0.59%)
Stock Index Futures Muted as Weak China Trade Data Weighs on Sentiment

June S&P 500 futures (ESM23) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.09% this morning as weak trade data from China stoked investor concerns over the strength of global demand....

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
PACW : 7.54 (-2.71%)
WAL : 86.21 (+0.97%)
INTC : 23.52 (+2.31%)
AMD : 104.74 (+0.75%)
COIN : 212.96 (+0.22%)
ITX.E.DX : 51.920 (-1.93%)
YEXT : 6.46 (-0.92%)
GDYN : 19.90 (-2.07%)
VXRT : 0.5231 (+5.66%)
DAWN : 9.87 (-16.50%)
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos: Q1 Earnings Snapshot

Glaukos: Q1 Earnings Snapshot

GKOS : 120.49 (-0.02%)
Glaukos Announces First Quarter 2023 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced...

GKOS : 120.49 (-0.02%)
Glaukos Announces the Release of its 2022 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to...

GKOS : 120.49 (-0.02%)
Glaukos Submits New Drug Application to U.S. FDA for iDose TR

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos: Q4 Earnings Snapshot

Glaukos: Q4 Earnings Snapshot

GKOS : 120.49 (-0.02%)
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos Announces Participation in the Citi Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to...

GKOS : 120.49 (-0.02%)
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.49 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an...

See More

Key Turning Points

3rd Resistance Point 128.28
2nd Resistance Point 126.29
1st Resistance Point 123.39
Last Price 120.49
1st Support Level 118.50
2nd Support Level 116.51
3rd Support Level 113.61

See More

52-Week High 163.71
Fibonacci 61.8% 133.22
Fibonacci 50% 123.81
Last Price 120.49
Fibonacci 38.2% 114.39
52-Week Low 83.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements